Braun: $1B state investment in Indiana’s life sciences expected to create 100K jobs

2026-03-17T14:22:45-04:00March 17, 2026|

This post was originally published by Indianapolis Business Journal. Click here to read the original article. Seeking to position Indiana as a global leader in agritechnology and life sciences, Gov. Mike Braun unveiled a lofty goal in a public announcement Tuesday morning. Speaking at a press conference with Secretary of Commerce David Adams, Braun said the state will invest $1 billion over 10 years to boost life sciences-related businesses, with the goal of creating 100,000 jobs in those sectors. Braun said the new investment into human therapeutics, animal health, agritech, biotechnology and environmental innovation are part of his goal to create regional economic development plans by region. He said the Central Indiana Regional Development Authority, or CIRDA, will serve as the first “regional steward” over the initiative. CIRDA, an economic development alliance, represents more than 30 cities, towns and [...]

IU LAB marks a year of industry partnerships, bioscience startup growth, student innovation

2026-02-02T19:10:20-05:00February 2, 2026|

This post was originally published by Indiana University. Click here to read the original article. The IU Impact: We are advancing bioscience research and innovation, commercialization, industry collaboration and workforce development to grow Indiana’s life sciences economy and improve lives across the state. Indiana is a thriving hub of bioscience innovation, recognized globally as a leader in areas like drug discovery, orthopedics, medical devices, radiopharmaceuticals and neuroscience research. At the center of this momentum is Indiana University, where faculty, staff and students are harnessing IU’s $1 billion research enterprise to strengthen Indiana’s booming $99 billion life sciences economy. In 2023, IU President Pamela Whitten announced a historic investment to accelerate bioscience innovation and improve human health. That commitment was further cemented in 2024 with the launch of the IU Launch Accelerator for Biosciences. Supported by a $138 million Lilly Endowment Inc. grant, IU LAB [...]

Lilly and IU to expand access to clinical trials and latest innovative treatments for Hoosiers

2026-01-23T09:29:52-05:00December 3, 2025|

This post was originally published by Indiana University. Click here to read the original article. Collaboration aims to build best-in-class clinical trial innovation ecosystem in Indiana while strengthening Alzheimer’s disease clinical care and research and supporting life sciences talent development INDIANAPOLIS — A new agreement under which Eli Lilly and Company will provide up to $40 million to Indiana University aims to expand access to clinical trials in Indiana, giving patients a critical pathway to Lilly’s latest investigational and innovative medicines while surrounding them with exceptional care. The agreement builds on a decades-long partnership between the two entities and focuses on creating a best-in-class system for clinical trial innovation, strengthening Alzheimer’s disease clinical care and research, and developing the future scientific and clinical talent for Indiana’s growing life sciences sector. The five-year agreement leverages IU’s research and clinical expertise [...]

WSJ: How Eli Lilly Developed a COVID Drug in the Pandemic’s Long Shadow

2021-01-14T11:10:14-05:00November 13, 2020|

A recent Wall Street Journal (WSJ) article outlines the unusual and extraordinary steps one of CICP's board member companies Eli Lilly and Co. had to take to develop a new antibody-based drug for COVID-19 that has now been approved by the U.S. Food and Drug Administration (FDA) for emergency use. The article states "What Lilly has gone through to get to this point reflects not only the common challenges all businesses face in the pandemic, but also unique ones that push drugmakers to the limit of their ability to operate." The WSJ article has been republished and can be found HERE.

Go to Top